Hyderabad News Desk

DelveInsight Business Research LLP

DelveInsight’s “Congenital Hyperinsulinism (CHI) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Congenital Hyperinsulinism, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Highlights 

• Key Companies working on Congenital HyperInsulinism  Disease include Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and many others.

• Key Therapies included in the Congenital HyperInsulinism  Disease market include HM15136, Dasiglucagon, Glucagon and many others 

Congenital HyperInsulinism Overview

Congenital Hyperinsulinism is characterized by inappropriate and unregulated insulin secretion from the β cells of the pancreas. In CHI, the β cells release insulin inappropriately, and insulin secretion is not regulated by the blood glucose level (as occurs normally). The action of insulin causes hyperinsulinemic hypoglycemia. High insulin levels prevent the formation of ketone bodies, which means that the brain is deprived of its most important fuel (glucose), and ketone bodies are used as alternative fuels.

As Congenital HyperInsulinism is a congenital condition, a child shows symptoms within the first few days of life, although very occasionally, symptoms may appear later in infancy. Symptoms of hypoglycemia can include floppiness, shakiness, poor feeding, and sleepiness, all of which are due to low blood glucose levels. Seizures (fits or convulsions) can also occur due to low blood glucose levels. If the child’s blood glucose level is not corrected, it can lead to loss of consciousness and potential brain injury.

Congenital HyperInsulinism  Disease Epidemiology Insights

• In the year 2021, the total diagnosed prevalent cases of Congenital Hyperinsulinism were 15,487 in the 7MM which is expected to grow during the study period, i.e., 2019–2032.

Click here to learn more about the Congenital HyperInsulinism Disease Market Landscape

The Report Covers the Congenital Hyperinsulinism  Disease Epidemiology Segmented by:

• Congenital HyperInsulinism prevalent cases 

• Congenital HyperInsulinism incident cases 

• Congenital HyperInsulinism treatment cases 

• Congenital HyperInsulinism diagnosed cases 

Congenital HyperInsulinism Disease Market Outlook 

There is only one approved therapy for Congenital HyperInsulinism in the market, namely, PROGLYCEM (diazoxide) – a non-diuretic benzothiadiazine derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals.

A number of children with Congenital HyperInsulinism are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide/lanreotide, is required in such children. Somatostatin receptor analogs (SSRAs), typically octreotide/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long‐acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long‐acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that the severity of CHI may naturally reduce over time, the use of fixed‐dose long‐acting SSRAs may be considered disproportionate.

According to DelveInsight, the Congenital Hyperinsulinism (CHI) market in 7MM is expected to witness a major change in the study period 2019–2032.

Key Companies Working in the Congenital HyperInsulinism Market

Zealand Pharma

Rezolute

Hanmi Pharmaceutical

Crinetics Pharmaceuticals

And many others 

Congenital HyperInsulinism Therapies Covered and Analyzed in the Report

• RZ358

• HM15136

• Lanreotide Autogel

• Glucagon

And many others

Learn more about the Key Companies and Emerging Therapies in the Congenital HyperInsulinism Disease Market

 Table of Contents 

1.  Key Insights 

2.  Congenital HyperInsulinism  Disease  Introduction 

3.  Executive Summary of Congenital HyperInsulinism  Disease            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Congenital HyperInsulinism  Disease  Emerging Therapies

7.  Congenital HyperInsulinism  Disease  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Congenital HyperInsulinism Disease Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services